Cp. Speer et al., RANDOMIZED CLINICAL-TRIAL OF 2 TREATMENT REGIMENS OF NATURAL SURFACTANT PREPARATIONS IN NEONATAL RESPIRATORY-DISTRESS-SYNDROME, Archives of Disease in Childhood, 72(1), 1995, pp. 8-13
Aims-To compare treatment regimens of two widely used natural surfacta
nt preparations Curosurf and Survanta in respiratory distress syndrome
(RDS). Methods-The effects of the two treatment regimens on gas excha
nge, ventilatory requirements, and 28 day outcome in infants with RDS
were compared. Seventy fire preterm infants (birth weight 700-1500 g)
with RDS requiring artificial ventilation with an FIO2 of greater than
or equal to 0.4, were randomly selected at 1-24 hours of age. One gro
up received an initial dose of Curosurf (200 mg/kg); the other group S
urvanta (100 mg/kg). Patients who remained dependent on artificial ven
tilation with an FIO2 of greater than or equal to 0.3 received up to t
wo additional doses of Curosurf (each of 100 mg/kg) after 12 and 24 ho
urs or up to three additional doses of Survanta (each of 100 mg/kg) be
tween six and 48 hours after the initial dose. Results-There was a rap
id improvement in oxygenation and ventilatory requirements were reduce
d in both groups. However, infants treated with Curosurf had a higher
arterial:alveolar oxygen tension ratio and required a lower peak inspi
ratory pressure and mean airway pressure at several time points within
24 hours of randomisation (p<0.05-0.001). The incidences of pneumotho
rax in the Curosurf and Survanta groups were 6% and 12.5%, respectivel
y; the corresponding figures for grades 3-4 intracerebral haemorrhage
were 3% and 12.5%, respectively. Mortality was 3% in the Curosurf grou
p and 12.5% in the Survanta group. However, these differences did not
reach significance. Conclusion-The Curosurf treatment regimen resulted
in a more rapid improvement in oxygenation than Survanta and reduced
ventilatory requirements up to 24 hours aft er start of treatment. Thi
s was associated with a trend towards reduced incidence of serious pul
monary and nonpulmonary complications.